There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure NV (QURE – Research Report), Tocagen Inc (TOCA – Research Report) and G1 Therapeutics Inc (GTHX – Research Report) with bullish sentiments.
uniQure NV (QURE)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on uniQure NV, with a price target of $73. The company’s shares closed yesterday at $53.99, close to its 52-week high of $59.45.
“Our $73 price target is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single- arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during 2H22, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $765M, during 2028. We assume a launch price of $850K, which could be an underestimate based on the 7 plus years of anticipated durability.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.1% and a 47.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Mersana Therapeutics Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $69.71, which is a 29.1% upside from current levels. In a report issued on February 25, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $81 price target.
Tocagen Inc (TOCA)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Tocagen Inc today and set a price target of $14.50. The company’s shares closed yesterday at $10.92.
“We maintain our Buy rating of Tocagen and our 12-month price target of $14.50 per diluted share. We derive our price target based on a risk-adjusted NPV analysis of projected Toca 511 + Toca FC revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.6% and a 35.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Leap Therapeutics Inc, and Tyme Technologies Inc.
Tocagen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25, a 128.9% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $25 price target.
G1 Therapeutics Inc (GTHX)
H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc today and set a price target of $72. The company’s shares closed yesterday at $18.46, close to its 52-week low of $15.21.
“We are lowering our price target to $72, from $75, due to reduced 2019 estimated cash per share as we raised our expense assumptions. We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC.”
According to TipRanks.com, White is a 5-star analyst with an average return of 13.3% and a 47.1% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.